Skip to main content
. Author manuscript; available in PMC: 2018 Nov 1.
Published in final edited form as: J Thorac Oncol. 2017 Aug 14;12(11):1611–1625. doi: 10.1016/j.jtho.2017.08.002

Figure 4.

Figure 4

Crizotinib-resistant ROS1 mutations. (A) Crizotinib-resistant secondary ROS1 mutations reported to date, mapped on the structure data of ROS1 kinase domain (left) in complex with crizotinib (PDB:3ZBF). Analogous ALK resistance mutations are mapped on the ALK kinase domain in complex with crizotinib (PDB:2XP2) on the right, revealing structural similarities. Note: The ALK mutation analogous to ROS1 L1951R has not been reported and is therefore not shown. (B) The activity of ROS1-directed tyrosine kinase inhibitors against known crizotinib-resistant ROS1 mutations. This table is based on the available preclinical data, not all of which have been validated in the clinic.